Navigation Links
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
Date:9/17/2009

BRISBANE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).

The database, which includes DNA from approximately 1,500 IPF patients, is the largest in the world and offers researchers an opportunity to gain important new insights regarding the pathogenesis of this devastating disease. This announcement comes during the 2009 National Pulmonary Fibrosis (PF) Awareness Week, which is taking place this year September 14 - 21, 2009.

"This is an ideal partnership that will enhance our chances to make breakthroughs in understanding the causes of this disease, the optimal diagnostic strategies and the best prognosticators for patient outcomes," said David Schwartz, MD, the principal investigator of this research.

"We are pleased to be able to partner with National Jewish Health, one of the world's leading institutions in pulmonary medicine, in this important pursuit to better understand the role that genetic factors may play in the development of IPF, a disease that claims approximately 40,000 lives per year," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "With nearly a decade of experience in IPF research and development, we are committed toward advancing care for patients with this uniformly fatal disease who currently hav
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: ... and pharmaceutical raw materials,for use in pharmaceutical, nutraceutical ... financial results second quarter 2008 which,ended June 30 ... markets close., Huifeng,s earnings release and related ...
... 4 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... quarterly royalty payment of approximately $2.1 million ... Memantine for the treatment of,moderate-to-severe Alzheimer,s disease. ... quarterly royalty payments on certain,sales of Memantine ...
... announced partnership, Grid Dynamics and GridGain teamed up to develop the ... ... San Francisco, CA (PRWEB) August 4, 2008 -- Following ... up to develop the largest publicly known grid scalability test for ...
Cached Biology Technology:Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 2Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 3
(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ... of these patients generate resistance to the drug and, ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... The University of Miami,s Rosenstiel School of Marine and ... E.M. Rickaby, Ph.D., as recipient of the 2009 Rosenstiel ... Fellow of Wolfson College, Rickaby works in the Department ... current research on the interaction between marine phytoplankton and ...
... of years, green plants have employed photosynthesis to capture ... A goal of scientists has been to develop an ... produce liquid fuels from carbon dioxide and water. Researchers ... Laboratory (Berkeley Lab) have now taken a critical step ...
... the sea, and are responsible for providing nearly half of ... However, unlike their counterparts on land, the marine plants ... human sight. Consequently, we are still in a very ... phytoplankton biology and ecology. In a new paper published ...
Cached Biology News:Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 2Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 3Turning sunlight into liquid fuels 2Turning sunlight into liquid fuels 3A new view of oceanic phytoplankton 2A new view of oceanic phytoplankton 3
Request Info...
Sterile, individually wrapped, 4mm Cuvettes...
versican (H-56)...
... S1 Nuclease degrades single-stranded DNA and ... Double-stranded nucleic acids (DNA:DNA, DNA:RNA or ... with extremely high concentrations of enzyme ... remove single-stranded termini from double-stranded DNA ...
Biology Products: